Dyslipidemia management update

Current Opinion in Pharmacology
Yingzi Chang, Jacques Robidoux

Abstract

Association of hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD) is well established. Reducing low-density lipoprotein-cholesterol (LDL-C) and raising high-density lipoprotein-cholesterol (HDL-C) have been the therapeutic targets to reduce the risk of ASCVD. Cholesterol-lowering medications have been used to provide both primary and secondary prevention of ASCVD for many years by reducing the absorption and reabsorption, promoting excretion, or decreasing the synthesis of cholesterol. Within the past five years, several new classes of cholesterol-lowering drugs have been tested and approved for patients with hypercholesterolemia that are not well controlled by conventional therapy (ezetimibe, bile-acid sequestrants, and statins). These drugs include proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies, apolipoprotein A-100 (Apo B-100) antisense, and microsomal triglyceride transfer protein (MTP) inhibitor. Clinical trials revealed that adding PCSK9 antibodies to the preexisting statin therapy can further reduce LDL-C by 60%. ApoB antisense and MTP inhibitor are currently approved for patients with homozygous familial hypercholesterolemia. Several HDL-raising drugs have also been tested, but the...Continue Reading

Citations

Jun 8, 2017·Children·Francesco Massimo PerlaCaterina Anania
Jan 19, 2018·Expert Review of Clinical Pharmacology·Julie Rask LarsenPeter Manu
Jan 25, 2018·Pharmacy : Journal of Pharmacy, Education and Practice·Donatella ZoddaSilvia Schifilliti
Dec 13, 2017·Expert Opinion on Drug Metabolism & Toxicology·Arrigo F G CiceroClaudio Borghi
Mar 27, 2018·Annals of Medicine·Najmeh AhangariAlireza Pasdar
Nov 6, 2018·International Journal of Molecular Sciences·Asier Benito-VicenteCesar Martin
Mar 20, 2019·Internal Medicine Journal·Yee-Ming CheungElif I Ekinci
Sep 21, 2018·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Massimo VolpeUNKNOWN Scientific Societies
Sep 20, 2018·Hormones : International Journal of Endocrinology and Metabolism·Niki Katsiki, Dimitri P Mikhailidis
Oct 2, 2020·The Journal of Nutrition·Francois BlachierAnne Blais

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

Revista médica de Chile
Ada CuevasRodrigo Alonso
Current Treatment Options in Cardiovascular Medicine
Michael J Wilkinson, Michael H Davidson
Diabetes & Metabolism Journal
Chang Ho Ahn, Sung Hee Choi
© 2022 Meta ULC. All rights reserved